Skip to main content
Analytics and reporting

The panel as a single rollup, plus reports AriaMD writes for you.

Available on Provider+. Clinical-study and custom-export modes are enterprise.

Outcomes at the cohort level

Response and remission across the panel.

PHQ-9, GAD-7, COWS, and any custom scale you score. Switch cohort for depression, anxiety, MAT, TMS, and Spravato. Built from the same signed encounters as each chart.

nextvisit.app/analytics/outcomes
Wk 0Wk 4Wk 8Wk 12Wk 16ResponseRemission
PHQ-9 6.2at week 16, mean
66% lowervs baseline
Depressioncohort selected

Response and remission bands use standard cutoffs. Click a cohort pill to swap the scale. Any aggregate drills to the patients underneath.

Practice performance

Active panel, no-show rate, NPS, days in AR, top meds, top diagnoses.

Hover the diagnosis donut to filter the top-medications bar by indication. KPIs refresh on any chart change.

nextvisit.app/analytics/practice
0
Active panel
across all providers
0.0%
No-show rate
last 30 days
0
Net promoter
clinician NPS
0
Days in AR
mean across payers
Top medications
  • Sertraline312
  • Bupropion254
  • Lamotrigine198
  • Vyvanse174
  • Lithium142
  • Buspirone121
Top diagnoses
  • Depression38%
  • Anxiety27%
  • ADHD14%
  • Bipolar11%
  • Other10%
AI review and data evaluation

Workspace data, written up like a study.

Sample size, methods, results, and the source encounters and codes. AriaMD writes it. You read the abstract.

nextvisit.app/analytics/reports/mat-weekly
Workspace report · weekly

MAT outcomes, week ending 04-19-2026

n = 312 active inductions generated by AriaMD cohort 2024-Q1 to 2026-Q1

Abstract

Across 312 buprenorphine inductions over 8 quarters, retention at 90 days was 78%, with COWS reduction of 9.4 (95% CI 8.7 to 10.1) from baseline. Concurrent counseling participation averaged 71% (n=222 of 312). 14 inductions were terminated for diversion concerns; 7 of 14 transitioned to a higher level of care.

Methods

Retrospective analysis of all signed encounters tagged MAT in the workspace. COWS scores, UDS results, and counseling attendance pulled from the structured fields on each visit note. No free-text mining; results derive from the same fields the chart uses.

Results

  • Retention 90 days: 78% (243 of 312)
  • COWS reduction baseline to wk 12: 9.4 (CI 8.7 to 10.1)
  • UDS positive for prescribed buprenorphine at wk 12: 92%
  • Counseling adherence: 71% mean across cohort
  • Adverse events: 4 documented, 0 serious
Sources: 5,847 signed encounters · 312 charts referenced · ICD-10 F11.10, F11.20, F11.21 · model behavior monitored

Every claim links to the source encounters. Counts come from structured fields on signed notes. Enterprise adds longer cohort windows, multi-workspace pooling, and custom CI methods.

AriaMD-authored reports

Scheduled reports, delivered in any format you specify.

Write a prompt. Pick a cadence and a delivery target. AriaMD runs unattended.

nextvisit.app/automations/scheduled-report
AriaMD promptRecurring · Mon 09:00

PatientsEncountersDocumentsWeb search
DeliveryPDF · branded
  • Daily, weekday, weekly, monthly, or event-triggered cadence
  • PDF, CSV, JSON, Markdown, plain email, or a layout you describe in the prompt
  • Email to a clinician or list, automation event, or webhook
  • Patients and Encounters on by default; Documents and web search opt in
  • 10,000 prompt characters, four intelligence levels, scoped tools per task
What you need to run it

Provider+ for the dashboards and scheduled reports.

Outcomes, practice performance, and AriaMD-authored reports ship on Provider+. Enterprise adds clinical-study mode, multi-workspace pooling, custom export formats, brand templates, and longer cohort windows.

See pricing Talk to sales for enterprise
See your panel as a single rollup

Twenty minutes. We open one of your real workspaces (or a sample) and walk the analytics view.

Cohort outcomes, practice KPIs, a study-grade rollup, and one scheduled report to your inbox.

Book a demo Talk to sales
Live in 2 weeks or less BAA signed by default